- Home
- EGRX vs LEXX Comparison
EGRX vs LEXX Comparison
Compare EGRX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGRX
- LEXX
- Stock Information
- Founded
- EGRX 2007
- LEXX 2004
- Country
- EGRX United States
- LEXX Canada
- Employees
- EGRX N/A
- LEXX N/A
- Industry
- EGRX Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- EGRX Health Care
- LEXX Health Care
- Exchange
- EGRX Nasdaq
- LEXX Nasdaq
- Market Cap
- EGRX 50.7M
- LEXX 49.3M
- IPO Year
- EGRX 2014
- LEXX N/A
- Fundamental
- Price
- EGRX $1.99
- LEXX $3.19
- Analyst Decision
- EGRX
- LEXX Strong Buy
- Analyst Count
- EGRX 0
- LEXX 2
- Target Price
- EGRX N/A
- LEXX $11.00
- AVG Volume (30 Days)
- EGRX 321.6K
- LEXX 96.5K
- Earning Date
- EGRX 11-12-2024
- LEXX 11-18-2024
- Dividend Yield
- EGRX N/A
- LEXX N/A
- EPS Growth
- EGRX N/A
- LEXX N/A
- EPS
- EGRX 0.91
- LEXX N/A
- Revenue
- EGRX $257,551,000.00
- LEXX $411,019.00
- Revenue This Year
- EGRX N/A
- LEXX $82.02
- Revenue Next Year
- EGRX N/A
- LEXX $95.09
- P/E Ratio
- EGRX $2.35
- LEXX N/A
- Revenue Growth
- EGRX N/A
- LEXX 34.05
- 52 Week Low
- EGRX $1.80
- LEXX $0.85
- 52 Week High
- EGRX $14.78
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- EGRX 19.60
- LEXX 48.73
- Support Level
- EGRX $1.80
- LEXX $2.91
- Resistance Level
- EGRX $4.11
- LEXX $3.39
- Average True Range (ATR)
- EGRX 0.40
- LEXX 0.20
- MACD
- EGRX -0.19
- LEXX 0.00
- Stochastic Oscillator
- EGRX 6.86
- LEXX 56.00
About EGRX Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.